Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immuno-NF2 Main Study: VEGFR1/2 Peptide Vaccine in NF2-related Schwannomatosis
jRCT2031240607Recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Jul 2025
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Randomised, double-blind trial in neurofibromatosis type 2 (NF2) and acoustic neuroma comparing OCV-101/OTS-102 vaccine with Placebo (2 arms). Primary endpoint: Time to disease progression of vestibular schwannoma. Started Jul 2025; status: recruiting.
02
Drugs
OCV-101OTS-102
03
Conditions
neurofibromatosis type 2 (NF2)acoustic neuroma
Beyond the preview
Go deeper on jRCT2031240607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240607.